Baker Brothers files Form 144 for TARA stock sales

Baker Brothers Life Sciences filed a Form 144 reporting proposed sales of Common Stock of TARA.

Accepted by SEC EDGAR 03/06/2026 - 05:50 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Baker Brothers Life Sciences filed a Form 144 reporting proposed sales of Common Stock of TARA. The filing lists three brokered sales: 322,039 shares on 02/24/2026 for $1,944,922; 947,479 shares on 02/25/2026 for $5,501,316; and 424,125 shares on 03/04/2026 for $2,654,641.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did the Form 144 for TARA disclose?

It disclosed proposed brokered sales of TARA common stock by Baker Brothers Life Sciences. The filing lists three sales on 02/24/2026, 02/25/2026, and 03/04/2026 with share counts and dollar amounts shown for each transaction.

How many shares did Baker Brothers sell on February 25, 2026 for TARA?

Baker Brothers sold 947,479 shares on 02/25/2026. The filing pairs that share count with a reported gross amount of $5,501,316, indicated as a brokered transaction in the Form 144 excerpt.

What proceeds are shown for the March 4, 2026 TARA sale?

The March 4, 2026 sale is reported as 424,125 shares for $2,654,641. That figure appears alongside the sale date and share count in the Form 144 excerpt, identified as a brokered Common Stock sale by Baker Brothers Life Sciences.

Who is the reporting seller in this Form 144 for TARA?

The seller reported is Baker Brothers Life Sciences, L.P. The excerpt lists that entity's name and address for each sale entry and identifies the transactions as Common Stock brokered sales on the specified dates.

Does the Form 144 indicate how the sales were executed for TARA shares?

Yes; the excerpt identifies the transactions as brokered sales. Each sale line pairs a date, share count, and gross dollar amount and lists the sales method as broker, consistent with the brokered sale entries in the Form 144 excerpt.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001363364
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Protara Therapeutics, Inc.
SEC File Number	001-36694
Address of Issuer	345 Park Avenue South Third Floor New York NEW YORK 10010
Phone	646-844-0337
Name of Person for Whose Account the Securities are To Be Sold	Baker Brothers Life Sciences, L.P.
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Former Affiliate

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common Stock	Canaccord Genuity LLC 99 High Street, Suite 1200 Boston MA 02110	461723	2701080.00	53587260	03/06/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common Stock	03/06/2026	See Remark 2	Broker			461723	03/06/2026	See Remark 2

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Baker Brothers Life Sciences, L.P. 860 Washington Street, 3rd Floor New York NY 10014	Common Stock	02/24/2026	322039	1944922.00
Baker Brothers Life Sciences, L.P. 860 Washington Street, 3rd Floor New York NY 10014	Common Stock	02/25/2026	947479	5501316.00
Baker Brothers Life Sciences, L.P. 860 Washington Street, 3rd Floor New York NY 10014	Common Stock	03/04/2026	424125	2654641.00

144: Remarks and Signature

Remarks	(1) Baker Brothers Life Sciences, L.P. is affiliated with 667, L.P. Baker Bros. Advisors LP is the investment adviser to 667, L.P. and Baker Brothers Life Sciences, L.P. 667, L.P. is filing separately for the sale of 38,277 shares of common stock ("Common Stock") of Protara Therapeutics, Inc. (the "Issuer"), which along with the reported sales in this form by Baker Brothers Life Sciences, L.P. totals 500,000 shares of Common Stock. (2) Common Stock borrowed from broker.
Date of Notice	03/06/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	By: BAKER BROS. ADVISORS LP, mgmt company and IA to Baker Brothers Life Sciences, L.P., /s/ Scott L. Lessing, President
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)